Month: August 2022

WVE-006 announced as investigational development candidate for AATD with CTA submissions expected in 2023; first-in-class RNA editing candidate and most advanced program currently in development using an oligonucleotide to harness an endogenous enzyme for editing Data for ongoing clinical programs, including WVE-004, WVE-003, and WVE-N531, expected in 2H 2022 Positive target engagement data in C9-ALS/FTD with single low doses of WVE-004 highlighted at ENCALS conference $70 million financing in June 2022 strengthened balance sheet and extended cash runway to the end of 2023 Wave to host investor conference call and webcast at 8:30 a.m. ET today CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...

BALTIMORE, Aug. 11, 2022 (GLOBE NEWSWIRE) — Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today provided an update on recent corporate developments and anticipated milestones, and reported financial results for the three and six months ended June 30, 2022. Recent Corporate DevelopmentsAnnounced review of strategic alternatives — On June 28, 2022, Graybug announced that its Board of Directors would conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. Alternatives being explored include the potential for an acquisition, company sale, merger, divestiture of assets, private placement of equity securities, or other strategic transactions. Further clinical development is on hold pending...

MISSISSAUGA, Ontario, Aug. 11, 2022 (GLOBE NEWSWIRE) — Next Hydrogen Solutions Inc. (the “Company” or “Next Hydrogen”) (TSXV:NXH, OTC:NXHSF), a designer and manufacturer of electrolyzers, is pleased to report its financial results for the second quarter ended June 30, 2022. “We are very proud of our team’s efforts to install the test infrastructure and commence system testing operations this quarter, despite some supply chain challenges,” said Raveel Afzaal, President and CEO of Next Hydrogen. “This essential capability will help accelerate the deployment of our innovative product lines in a cost-effective manner, de-risk our journey to large volume commercial sales, and establish a strong brand for Next Hydrogen.” Q2 2022 Financial HighlightsRevenue was $44,826 and $85,621, for the three-month and six-month period, compared...

Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for the second quarter and six months ended June 30, 2022 and provided an update on recent business events. Recent Corporate Highlights:CorMedix announced on August 8th that a second Complete Response Letter (CRL) was received from the FDA stating that the DefenCath NDA cannot be approved until deficiencies conveyed to the contract manufacturing organization (CMO) and the supplier of the active pharmaceutical ingredient (API) heparin during inspections are resolved to the satisfaction...

31% increase in branded cannabis net revenue1 to $10.0 million from $7.6 million in the prior year #12 ranking for market share in core markets2 for Q1 FY2023 In the Ontario value category, Divvy has attained #5 market share in pre-roll and #7 in flower Secured new international partnership representing approximately $4.6 million sales commitment 12% increase in medical cannabis net revenue3 over the prior quarter 7.5% market share in overall Canadian medical market Reaffirmed guidance of $53.0 to $63.0 million in net revenue in FY20234 Trending towards breakeven Adjusted EBITDA5 profitability with -$0.9 million in Q1 FY2023; reaffirmed guidance of achieving run-rate breakeven Adjusted EBITDA in FY20236 Nitecaps, a breakthrough melatonin-CBD product launch in current quarterTORONTO, Aug. 11, 2022 (GLOBE NEWSWIRE) — Aleafia...

Reaffirms start of production this quarter in BicesterATM platform established to access additional capitalMOUs and Orders worth over $6b in potential revenue LUXEMBOURG, Aug. 11, 2022 (GLOBE NEWSWIRE) — Arrival (NASDAQ: ARVL), inventor of a unique new method of design and production of equitable electric vehicles (EVs) by local Microfactories, today reported financial results for the second quarter ended June 30, 2022. “We have had big achievements in Q2 including the European certification of our Van and Bus products and successful internal trials of both Van and Bus on public roads. In addition, we’ve made recent strategic decisions that will allow us to start production this quarter in Bicester (UK), deliver our first vehicles to UPS this year, and start production in Charlotte (US) in 2023. We are excited to be drawing closer...

— Achieves Record Quarterly Revenues and EBITDA1 — MONTREAL, Aug. 11, 2022 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2022. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q2 2022 Highlights FinancialsRevenues were $75,820, an increase of $10,024 or 15% over the same period in prior year. Gross margin of $38,295 or 51% compared to $28,871 or 44% in the same period in prior year. Adjusted EBITDA1 was $17,890, an increase of $8,494 or 90% over the same period in prior year. Net loss on financial assets measured at fair value through profit or loss...

– Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid Tumors – – Cash Runway into Late 2024 with $299.5 Million in Cash, Cash Equivalents, Restricted Cash and Marketable Securities as of June 30, 2022 – BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the second quarter, ended June 30, 2022. “Over the last few months, we have made important progress in advancing our pipeline of molecular glue degraders, culminating most recently in the submission of our investigational new drug (IND) application for MRT-2359,” said Markus Warmuth, M.D., CEO of Monte Rosa....

HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) — Vantage Drilling International (“Vantage” or the “Company”) reported net income attributable to controlling interest of approximately $48.1 million, or  $3.61 per diluted share, for the three months ended June 30, 2022, based on the weighted average shares outstanding, as compared to a net loss attributable to controlling interest of $29.0 million, or $2.21 per diluted share, for the three months ended June 30, 2021. The net income is a result of the sale of the Emerald Driller Company (“EDC”) and its three jackup rigs, the Emerald Driller, the Aquamarine Driller, and the Sapphire Driller, which closed on May 27, 2022.  The Company received $170.0 million as purchase price consideration and $30.0 million in certain contract preparation expense reimbursements, and as a result,...

Net Revenue Up 66.4% with Comparable Growth of 65.2%Demand Comparable Growth of 22.5%Raising Full Year 2022 Outlook to Reflect Q2 Outperformance BOSTON HEIGHTS, Ohio, Aug. 11, 2022 (GLOBE NEWSWIRE) — Arhaus, Inc. (NASDAQ: ARHS; “Arhaus” or the “Company”), a rapidly growing lifestyle brand and omni-channel retailer of premium artisan-crafted home furnishings, reported financial results for the second quarter ended June 30, 2022. Second Quarter 2022 HighlightsNet revenue increased 66.4% to $306 million Comparable Growth(1) of 65.2% Net and Comprehensive Income of $37 million Adjusted Net Income of $39 million Adjusted EBITDA increased 76.4% to $60 millionYear-to-Date 2022 Highlights, through June 30Net revenue increased 55.5% to $553 million Comparable Growth of 53.1% Net and Comprehensive Income of $53 million Adjusted Net...